Download the pdf version here

Characteristics
Morphology Gram negative microaerophilic curved rod.
Disease

H. pylori are not invasive, but colonize in the human stomach's antral region and gastric mucosal surfaces where they release pathogenic proteins that induce cell injury and inflammation. This can result in clinical symptoms of infection, such as duodenal ulcer and gastric adenocarcinoma. Other common illnesses as a result of infection include gastroenteritis, diffuse antral gastritis, and gastric carcinoma. H. pylori is a Class I human carcinogen according to the World Health Organization. Infection can last a lifetime in the host if not properly treated, causing chronic gastritis which can lead to peptic gastroduodenal ulcer disease.
Zoonosis Yes, animals and humans and vice versa.
Health Hazards
Host Range Humans and animals
Modes of Transmission  With more than 50 % of the world’s population infected, acquisition is likely to occur during childhood through fecal-oral, oral-oral contact, or during gastrointestinal tract transit disorders.
Signs and Symptoms  Gastroenteritis and ulcers. Major symptoms are abdominal pain, heartburn, and nausea.
Infectious Dose unknown
Incubation Period  unknown.
Medical Precautions/Treatment
Prophylaxis None available.
Vaccines None available. 
Treatment Clarithromycin, amoxicillin, and tetracycline.
Surveillance Can be confirmed by culture, blood antigen detection, and urease detection
MSU Requirements  Report any exposures.
Laboratory Hazards
Laboratory Acquired Infections (LAIs) 3 reported cases.
 Sources May be located in the oral cavity, gastrointestinal and hepatobiliary regions. Cultures, frozen stocks, other samples described in IBC protocol.
Supplemental References
Canadian MSDS: http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php
BMBL https://www.cdc.gov/labs/BMBL.html 
CDC https://stacks.cdc.gov/view/cdc/40603
NIH Guidelines https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf
Risk Group & Containment Requirements
Risk Group 2

Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available.
BSL2
For all procedures involving suspected or known infectious specimen or cultures.
ABSL2
For all procedures utilizing infected animals.
Spill Procedures
Small
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed) of contact time. After 20 minutes, cleanup and dispose of materials.
Large
  • Immediately notify all personnel in the lab and clear all personnel from the area. Remove any contaminated PPE/clothing and leave the lab. 
  • Secure the area by locking doors, posting signage and guarding the area to keep people out of the space. 
For assistance, contact MSU's Biosafety Officer (406-994-6733) or Safety and Risk Management (406-994-2711).
Exposure Procedures
Mucous membrane
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
Other Exposures
Wash area with soap and water for 5 minutes.
Reporting
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
Medical Follow-up
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm.  Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT
Viability
Disinfection Susceptible to 1:10 bleach:water, 70 % ethanol
Inactivation Inactivated by moist heat (15 minutes at 121oC) and dry heat (10 minutes at 70oC followed by 5 mintues at 95°C). 
Survival Outside Host unknown
Personal Protective Equipment (PPE)
Minimum PPE Requirements
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
Additional Precautions
 Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol.